We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+1.18%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$704K
Cap. Flow
+$4.85M
Cap. Flow %
1.91%
Top 10 Hldgs %
43.68%
Holding
90
New
20
Increased
18
Reduced
11
Closed
40

Top Buys

Rank Stock Value
1
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.28M
2
TAK icon
Takeda Pharmaceutical
TAK
+$9.02M
3
SIEN
Sientra, Inc.
SIEN
+$8.62M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$8.05M
5
HUM icon
Humana
HUM
+$7.05M

Top Sells

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$13.8M
2
GILD icon
Gilead Sciences
GILD
+$10.1M
3
BMY icon
Bristol-Myers Squibb
BMY
+$9.55M
4
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$5.99M
5
EVH icon
Evolent Health
EVH
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 77.04%
2 Technology 6.14%
3 Industrials 4.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
51
AnaptysBio
ANAB
$1.58B
– –
-6,082
Closed -$444K
AXSM icon
52
Axsome Therapeutics
AXSM
$11.2B
– –
-52,268
Closed -$744K
BHC icon
53
Bausch Health
BHC
$2.58B
– –
-104,344
Closed -$2.58M
CNC icon
54
Centene
CNC
$30.7B
– –
-54,995
Closed -$2.92M
CVS icon
55
CVS Health
CVS
$133B
– –
-11,036
Closed -$595K
DVAX
56
DELISTED
Dynavax Technologies
DVAX
– –
-41,288
Closed -$302K
ELV icon
57
Elevance Health
ELV
$81.5B
– –
-9,084
Closed -$2.61M
EVH icon
58
Evolent Health
EVH
$348M
– –
-418,728
Closed -$5.27M
GILD icon
59
Gilead Sciences
GILD
$162B
– –
-155,793
Closed -$10.1M
HAE icon
60
Haemonetics
HAE
$3.89B
– –
-6,691
Closed -$585K
HSIC icon
61
Henry Schein
HSIC
$9.77B
– –
-10,503
Closed -$631K
ICLR icon
62
Icon
ICLR
$12.6B
– –
-100,874
Closed -$13.8M
KRYS icon
63
Krystal Biotech
KRYS
$10.1B
– –
-61,155
Closed -$2.01M
LIVN icon
64
LivaNova
LIVN
$4.4B
– –
-42,312
Closed -$4.12M
MDT icon
65
Medtronic
MDT
$109B
– –
-35,579
Closed -$3.24M
MOH icon
66
Molina Healthcare
MOH
$10.2B
– –
-5,830
Closed -$828K
OCUL icon
67
Ocular Therapeutix
OCUL
$1.79B
– –
-716,124
Closed -$2.84M
PTCT icon
68
PTC Therapeutics
PTCT
$5.68B
– –
-16,903
Closed -$636K
QQQ icon
69
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-16,600
Closed -$2.98M
SPY icon
70
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
– –
-37,100
Closed -$10.5M
TDOC icon
71
Teladoc Health
TDOC
$1.22B
– –
-13,153
Closed -$731K
THC icon
72
Tenet Healthcare
THC
$20.5B
– –
-121,823
Closed -$3.51M
TMO icon
73
Thermo Fisher Scientific
TMO
$213B
– –
-10,500
Closed -$2.87M
VCEL icon
74
Vericel Corp
VCEL
$2.35B
– –
-123,111
Closed -$2.16M
VKTX icon
75
Viking Therapeutics
VKTX
$3.7B
– –
-178,448
Closed -$1.77M
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Endurant Capital Management held 90 positions worth $254M, up 0.28% from $253M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Endurant Capital Management's Q2 2019 filing shows 20 new, 18 increased, 11 reduced and 40 closed positions. Its largest new stake was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M. The largest sale was Icon, an estimated $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Technology and Industrials.

  • Endurant Capital Management's largest Q2 2019 buy was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
  • Endurant Capital Management added most to Takeda Pharmaceutical in Q2 2019, an estimated $9.02M increase.
  • Endurant Capital Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $9.55M.
  • Endurant Capital Management fully exited Icon in Q2 2019, selling an estimated $13.8M.
  • Endurant Capital Management's ten largest holdings make up 44% of its $254M portfolio in Q2 2019.
  • Endurant Capital Management opened 20 new positions and closed 40 in Q2 2019.
  • Endurant Capital Management's portfolio value rose 0.28% quarter-over-quarter to $254M.

Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.